National Taiwan University    |     NTU, College of Medicine
NTU, Department of Pharmacy
Graduate Institute of Clinical Pharmacy
Drug Research Center    |     Ching Kang Foundation
Center for Innovative Therapeutics Discovery
NTUH,Department of Pharmacy
Taiwan Society of Health-System Pharmacists
Alumni    |     Alumni in North America    |     AASP    |    
Instrumentation Booking System    |     Platform for Research and Inspiration in Regulatory Science
© copyright 2014 SP, NTU. All Rights Reserved.
No.33, Linsen S. Rd., Zhongzheng Dist., Taipei City 100025, Taiwan (R.O.C.)
TEL : (02)3366-8750~4    FAX : (02)2391-9098
Web person in charge: Tang-Yih Hsu
Contact Phone : (02)33668743
Latest Update : 2025 / 02 / 18
Privacy & Security Policy
News
back
Posted Type : International
Posted Time : 2025-02-14 13:07:54
Applying Pharmacometrics to Enhance Translational Development and Clinical Use of Drug Therapies




Topic: Applying Pharmacometrics to Enhance Translational Development and Clinical Use of Drug Therapies

Speaker: Prof. Mitch A. Phelps
College of Pharmacy, Ohio State University

Time: 2 / 20 / 2025(THU)
10:00~11:00 AM

Place: Webex seminar

About Prof. Mitch A. Phelps
Dr. Phelps’ lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).

In this talk, Prof. Phelps will give an overview of their works at OSU, which will include brief introduction on several projects, potentially including: first-in-human study design/implementation for a novel DHODH inhibitor, optimal sampling design for abemaciclib/olaparib in experimental cancer trials and dealing with sparse/imperfect data, PK-guided dosing of melphalan in autologous transplant, use of modeling/simulation for TDM of busulfan, evaluating cefepime PK in patients receiving renal replacement therapy, aspirin pharmacology and biomarker discovery for prevention of preeclampsia in pregnancy, and translational modeling/simulation to evaluate mechanistic hypotheses for immunotherapies in cancer cachexia. This will include studies in oncology/hematology, infectious disease, and maternal/fetal medicine.